Is Pharma at an ESG Turning Point?

In the global push to ESG-focused investing, the Pharma sector has traditionally been challenged. But RBC Capital Markets’ Daniel Busby, Pharmaceuticals Equity Research Analyst, suggests that this may be about to change. A combination of trends, some of them yet to appear on the public radar, could lift Pharma’s ESG market reputation and create new opportunities for investment and inclusion.